Summary & Overview
HCPCS S3850: Genetic Testing for Sickle Cell Anemia
HCPCS Level II code S3850 represents genetic testing for sickle cell anemia, a molecular diagnostic service used to identify pathogenic hemoglobin variants. This test is clinically important nationwide for confirming diagnoses, guiding family counseling, and informing therapeutic decisions in patients and carriers. Coverage and coding for genetic tests like S3850 affect access to definitive diagnosis and downstream care pathways across public and private payers. Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will find a concise overview of what S3850 denotes, typical sites where the service is performed, and which payers are relevant to coverage discussions. The publication outlines benchmarks and policy context affecting laboratory genetic testing reimbursement, highlights clinical implications of molecular sickle cell testing, and summarizes common billing and reporting considerations. Data not available in the input is noted where applicable. The content is designed for clinicians, laboratory billing staff, and policy analysts seeking a national-level briefing on coding and payer considerations for genetic testing for sickle cell anemia.
Billing Code Overview
HCPCS Level II code S3850 describes genetic testing for sickle cell anemia. The service is a diagnostic genetic test used to detect mutations associated with sickle cell disease and related hemoglobinopathies.
Typical site of service: clinical laboratory or specialized diagnostic facility where molecular testing is performed.
Service type: laboratory genetic testing focused on identifying causative variants for sickle cell anemia and informing diagnosis, carrier status, or clinical management decisions.
Clinical & Coding Specifications
Clinical Context
A 6-month-old infant of African descent presents to a pediatric genetics clinic after a newborn screen flagged an abnormal hemoglobin pattern suggestive of sickle cell disease. The infant's primary care pediatrician refers the family for diagnostic confirmation using targeted DNA analysis. In the genetics workflow, a phlebotomy appointment is scheduled at an outpatient laboratory or hospital outpatient phlebotomy suite. Specimens are collected and sent to a molecular diagnostics laboratory for S3850 - genetic testing for sickle cell anemia. The laboratory performs targeted testing of the HBB gene to identify pathogenic variants such as HbS (p.Glu6Val) and other common hemoglobinopathy mutations. Results are reported to the ordering pediatrician and genetic counselor, who communicate carrier status or disease confirmation to the family and coordinate follow-up care, including hematology referral when disease is confirmed. Typical sites of service include outpatient hospital laboratories, independent clinical molecular laboratories, and pediatric genetics or hematology clinics.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | Use when reporting only the professional (interpretation) component provided by a physician or qualified professional separate from the technical processing. |